BusinessSienna Biopharmaceuticals Announces First Patient Dosed in Proof-of-Concept Trial of Topical by Design™ JAK Inhibitor SNA-125 for Atopic DermatitisBy Nasdaq OMXMar 12, 2018, 10:05 AM UTC
BusinessSienna Biopharmaceuticals Establishes Corporate Advisory BoardBy Nasdaq OMXDec 12, 2017, 2:05 PM UTC
BusinessNovan Announces First Patient Dosed in Phase 1b Atopic Dermatitis Trial with SB414By Nasdaq OMXDec 5, 2017, 1:35 PM UTC
BusinessMatriSys Bioscience, Inc. Announces First Patient Dosed in Phase 2A Clinical Trial with Live Staphylococcus hominis Bacteria for the Treatment of Atopic DermatitisBy Nasdaq OMXAug 21, 2017, 10:00 AM UTC
BusinessClarification: Galectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXAug 18, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Reports 2017 Second Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXAug 14, 2017, 12:15 PM UTC
BusinessPatent for Reducing Inflammatory Response Granted to Galectin TherapeuticsBy Nasdaq OMXJun 21, 2017, 12:30 PM UTC
BusinessGalectin Therapeutics Reports 2017 First Quarter Financial Results and Provides Business UpdateBy Nasdaq OMXMay 15, 2017, 12:30 PM UTC
